CBT-004已在美国完成临床2期的首位病人入组
We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in December 2023 in the US. Pinguecula is a round, yellowish, elevated tissue that develops on the conjunctiva adjacent to the cornea. Cumulative exposure to UV light is the main cause […]
临床试验取得显著进展:CBT-009和CBT-004
We are proud to announce that CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA to enter into Phase 3 clinical trial in the USA. We have submitted our application to FDA for conducting a Phase 2 clinical trial in the United States to test […]
医药使我们能更好的视觉享受生活
Imagine a world where everyone can experience the joy and beauty of clear vision. At Cloudbreak, our mission is centered around the belief that vision is not just a sense but a gateway to a more fulfilling life. We strive to empower individuals by improving their vision and reducing the burden of eye disease. Through […]
Cloudbreak: 致力于改善视力健康的临床阶段公司
Perhaps you are unfamiliar with us and unsure of what motivates us to become a mission-driven company. Today, we are excited to share our story with you. Cloudbreak is a clinical-stage biotechnology company on a mission to improve the vision quality of people worldwide. We aim to help them see life better through medicine by […]
拨康视云入选2023年中国潜在独角兽企业
On June 20th, 2023, Greatwall Strategy Consultants (GEI) released the “2023 China Potential Unicorns Research Report”. Cloudbreak Pharma is honoured to be named one of the potential unicorn companies in China. The report showed that Suzhou ranked third in the country and first in the province in terms of number of potential unicorns with […]
拨康视云与眼视觉研究中心在香港签署战略合作备忘录
On May 17th, Cloudbreak Pharma Inc. (Cloudbreak) and Centre for Eye and Vision Research Ltd. (CEVR) signed a memorandum of understanding for strategic cooperation at the Asia Summit on Global Health (ASGH) in Hong Kong. The parties intend to explore opportunities to collaborate on research in ocular science and have reached a preliminary understanding of […]